scholarly journals Primary Chemotherapy in a 47-Year-Old Patient with Giant Ulcerative and Necrotizing Nonseminomatous Testicular Germ Cell Tumor

2021 ◽  
pp. 681-689
Author(s):  
Sophia Stock ◽  
Julian Marcon ◽  
Michael Chaloupka ◽  
Armin Becker ◽  
Wolfgang G. Kunz ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cell Cancer ◽  
Tumor Resection ◽  
Cell Tumor ◽  
Psychosocial Assessment ◽  
Primary Chemotherapy ◽  
Collaborative Group ◽  
Tumor Stages

Testicular cancer is a rare disease; however, cure rates are high for all tumor stages. Mostly, the disease is diagnosed in an early (local) stage. We report the case of a 47-year-old male patient with a giant nonseminomatous germ cell tumor. At the time of diagnosis, the patient demonstrated a necrotizing and ulcerating growing mass in the left scrotum with an approximate size of 22 × 18 cm. According to the prognostic classification of the International Germ Cell Cancer Collaborative Group (IGCCCG 1997), the patient exhibited a high-risk profile due to alpha-fetoprotein >10,000 ng/mL and lactate dehydrogenase >10× the upper limit of normal in serum. Primary orchiectomy was infeasible due to the tumor’s size, the patient’s poor general condition and initial intensive care unit treatment. Primary systemic chemotherapy was applied. After 3 cycles of cisplatin, etoposide and bleomycin, along with 1 cycle of cisplatin, etoposide and ifosfamide, tumor resection with histomorphological examination showed a complete pathological response. Despite the delayed initiation of the therapy, primary chemotherapy was completed timely and showed promising results. Reasons for the late hospitalization were personal responsibilities regarding his family. Better awareness and knowledge of testicular cancer among young men might prevent the here reported delay of medical consultation and avoid testicular tumors of such enormous size. Psychosocial assessment and distress management is important as an integral part of comprehensive care of testicular cancer patients.

scholarly journals Paclitaxel, Iphospamide, and Cisplatin (TIP) as Bleomycin, Etoposide, and Cisplatin (BEP) Alternative for First-Line Therapy of Metastatic Germ Cell Tumor (GCT): A Case Series

2019 ◽  
Vol 13 (3) ◽  
pp. 86
Author(s):  
Syamsu Hudaya ◽  
Adianti Khadijah
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cell Cancer ◽  
Hospital Setting ◽  
Cell Tumor ◽  
Collaborative Group ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Line Chemotherapy

Background: Bleomycin, etoposide, and cisplatin (BEP) is a standard first-line therapy for metastatic germ cell tumor (GCT), while paclitaxel, ifosfamide, and cisplatin (TIP) are commonly used as salvage therapy after failed BEP treatment. The unavailability of first-line drugs can be the reason for the use of second-line therapy. In this paper, we reviewed two initial cases of patients with metastatic GCT treated with TIP as first-line chemotherapy in our center.Case Presentation: We reviewed the medical record and followed up two patients who had been treated with TIP as first-line chemotherapy for metastatic GCT due to lack of BEP regiment. We evaluated efficacy and toxicity of this treatment. These two patients were diagnosed with seminoma, with intermediate-risk according to International Germ Cell Cancer Collaborative Group (IGCCCG) classification. Both achieved complete response after four courses of TIP chemotherapy with toxicities mainly consisted of myelosuppression.Conclusions: TIP demonstrated efficacy serves as the first-line therapy for germ cell tumors with an acceptable safety profile. Further studies with larger subjects are still needed for evaluation. However, TIP is more expensive compared to BEP, making BEP is still superior to TIP in public hospital setting where cost-effectiveness of treatment is important.

Non-seminomatous retroperitoneal histology in patients with a pure testicular seminoma and an elevated serum alpha feto-protein

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14561-14561 ◽  
Author(s):  
N. T. Karanikolas ◽  
F. P. Secin ◽  
J. Stasi ◽  
B. S. Carver ◽  
Z. Dotan ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Clinical Stage ◽  
Cell Cancer ◽  
Elevated Serum ◽  
Cell Tumor ◽  
Collaborative Group ◽  
Retroperitoneal Lymph Node Dissection ◽  
Cancer Specific Survival ◽  
Testicular Seminoma

14561 Background: There is controversy regarding the management of patients with pure testicular seminoma (PTS) and elevated alpha-fetoprotein (AFP) level (Nazeer, Oncol Rep 1998;5:1425). Our objective was to determine the retroperitoneal histology and clinical outcome of patients with pure testicular seminoma and elevated serum AFP level. Methods: Between 1989 and 2004, 15 patients with PTS and elevated AFP level underwent post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) at MSKCC. All diagnoses of PTS were confirmed by a MSKCC uropathologist. Clinical and pathologic data were obtained from our prospective surgical database and subsequently analyzed. Results: The median pretreatment AFP level was 339 ng/ml (interquartile range [IQR]: 42, 1,006). Clinical stage at initial presentation was IIa in 1, IIb in 1, IIc in 9, and III in 4. According to the International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, 6 patients had good, 6 had intermediate, and 3 had poor risk for disease. The histology at PC-RPLND demonstrated teratoma in 6 patients (40%), fibrosis/necrosis in 6 patients (40%), and viable germ cell tumor in 3 patients (20%; 1 embryonal, 1 yolk sac, and 1 seminoma). Overall, 8 of 15 (53%) had persistent nonseminomatous retroperitoneal histology after chemotherapy. At a median follow-up of 4.2 years (IQR: 2.3, 7.1), 10 patients were alive without disease, 2 were alive with disease, and 3 died of disease. Cancer-specific survival rate was 83% at 5 years (95% confidence interval: 47, 96). Conclusion: Contrary to prior reports (Nazeer, Oncol Rep 1998;5:1425), patients with pure seminoma and an elevated AFP level should be managed as having nonseminomatous germ cell tumor (GCT), including post chemotherapy RPLND because more than half will harbor either teratoma or viable GCT. No significant financial relationships to disclose.

Evidence for Altered Hypothalamic-Hypophyseal-Gonadal Axis in Untreated Patients with Testicular Germ-Cell Tumor

1989 ◽  
Vol 75 (5) ◽  
pp. 505-509
Author(s):  
Sergio Crispino ◽  
Gabriele Tancini ◽  
Sandro Barni ◽  
Paolo Lissoni
Keyword(s):  
Testicular Cancer ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Venous Blood ◽  
Germ Cell Tumors ◽  
Testicular Germ Cell Tumor ◽  
Cell Tumor ◽  
Testicular Germ Cell Tumors ◽  
Testicular Germ Cell ◽  
Significant Difference

To investigate the function of the hypothalamic-hypophyseal-gonadal axis in testicular germ cell tumors, we evaluated gonadotropin responses to gonadotropin-releasing hormone (GnRH) in 12 untreated patients with testicular cancer (5 seminomas and 7 non-seminomas). GnRH was given i.v. at a dose of 100 μg as a bolus, and venous blood samples were collected at 0, 20, 60, and 120 min. As controls, 14 healthy males were studied. Basal levels of testosterone, estradiol and prolactin were also detected in each patient. Hormonal serum concentrations were measured by the radioimmunoassay. Mean basal testosterone, estradiol and prolactin levels were not significantly different from those of controls. Patients had a lower FSH and LH peak after GnRH than controls, without, however, any significant difference. As regards histology, nonseminoma patients lacked an FSH response to GnRH and had statistically lower mean peak levels than controls. Moreover, non-seminoma patients had statistically lower mean peak values of LH after GnRH than controls. These data show that patients with testicular germ cell tumor, and more particularly those with non-seminomas, have an altered function of the hypothalamic-hypophyseal-gonadal axis, which is already present prior to therapy. Further studies, particularly in stage I patients treated only with orchiectomy, should be performed to confirm and better define the Physiopathologic significance of the altered hypothalamic-hypophyseal-gonadal axis in testicular cancer and to clarify the alteration of fertility, which is frequently present before treatment.

DERMATOMYOSITIS ASSOCIATED WITH INTRATUBULAR GERM CELL TUMOR AND METASTATIC GERM CELL CANCER

1998 ◽  
Vol 159 (6) ◽  
pp. 2096-2097 ◽  
Author(s):  
SHINSUKE HAYAMI ◽  
YOKO KUBOTA ◽  
ISOJI SASAGAWA ◽  
HITOSI SUZUKI ◽  
TERUHIRO NAKADA ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cell Cancer ◽  
Germ Cell Cancer ◽  
Cell Tumor

Primary chemotherapy for intracranial germ cell tumors: Results of the third international CNS germ cell tumor study

2010 ◽  
Vol 54 (3) ◽  
pp. 377-383 ◽  
Author(s):  
Nasjla Saba da Silva ◽  
Andrea M. Cappellano ◽  
Blanca Diez ◽  
Sergio Cavalheiro ◽  
Sharon Gardner ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Germ Cell Tumors ◽  
Cell Tumor ◽  
Primary Chemotherapy ◽  
The Third ◽  
Tumor Study ◽  
Intracranial Germ Cell Tumors ◽  
Cns Germ Cell Tumor

DERMATOMYOSITIS ASSOCIATED WITH INTRATUBULAR GERM CELL TUMOR AND METASTATIC GERM CELL CANCER

1998 ◽  
pp. 2096-2097 ◽  
Author(s):  
SHINSUKE HAYAMI ◽  
YOKO KUBOTA ◽  
ISOJI SASAGAWA ◽  
HITOSI SUZUKI ◽  
TERUHIRO NAKADA ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cell Cancer ◽  
Germ Cell Cancer ◽  
Cell Tumor

Successful treatment of non-midline primary malignant germ cell tumors with yolk sac components in neonates: report of 2 cases

2021 ◽  
Vol 27 (1) ◽  
pp. 47-51
Author(s):  
Alexander G. Weil ◽  
Natalie Mathews ◽  
Jean-Pierre Farmer ◽  
Christine St. Martin ◽  
Steffen Albrecht ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Successful Treatment ◽  
Tumor Resection ◽  
Germ Cell Tumors ◽  
Middle Cranial Fossa ◽  
Yolk Sac ◽  
Cell Tumor ◽  
Malignant Germ Cell Tumor ◽  
The Right

Here, the authors present 2 cases of nongerminomatous germ cell tumor (NGGCT): a neonate with a mixed malignant germ cell tumor, 5% yolk sac tumor (YST) and 95% immature teratoma components, originating from the right mesial temporal lobe; and a 2-month-old infant with a pure YST originating from the left middle cranial fossa. These tumors with yolk sac components, which are thought to have a poor prognosis, were successfully treated with complete tumor resection alone and subtotal tumor resection with chemotherapy, respectively. Event-free survival exceeds 5 years for each patient even though neither received radiotherapy. The authors highlight the role of radical surgery and the successful treatment of neonatal YST with aggressive resection (and chemotherapy in 1 case) while avoiding radiation therapy. They also report the very rare non-midline location of these neonatal NGGCTs and emphasize the importance of considering YSTs and mixed NGGCTs with YST components in the differential diagnosis of non-midline hemispheric or skull base tumors in newborns.

Sign in / Sign up

Export Citation Format

Share Document